Immunomedics (IMMU) Misses Q3 EPS by 6c

Immunomedics (NASDAQ: IMMU) reported Q3 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $500 million, versus $1.3 million reported last year.

For earnings history and earnings-related data on Immunomedics (IMMU) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Jiayin Group (JFIN) Reports Q2 Loss of RMB3.56
• Marvell Technology (MRVL) Tops Q2 EPS by 1c, Offers Guidance